2024 年业绩符合市场预期公司公布2024 年业绩：收入7.62 亿元，同比+14.4%；经调整净利润2.82亿元，同比+44.2%。2024 年业绩符合市场预期。发展趋势国内业务有所承压。2024 年分业务来看，出血/狭窄/急性缺血/通路收入同比增速分别为-5.5%/+74.6%/+82.0%/-26.7%。国内收入6.86 亿元，同比+8.3%，增速有所放缓。我们判断其中出血性脑卒中和通路...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.